Display options
Cite
Ansari S, Djalali M, Mohammadzadeh Honarvar N, et al. The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Int J Endocrinol Metab. 2017;15(1):e40614doi: 10.5812/ijem.40614.
Ansari, S., Djalali, M., Mohammadzadeh Honarvar, N., Mazaherioun, M., Zarei, M., Agh, F., Gholampour, Z., & Javanbakht, M. H. (2017). The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. International journal of endocrinology and metabolism, 15(1), e40614. https://doi.org/10.5812/ijem.40614
Ansari, Samaneh, et al. "The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial." International journal of endocrinology and metabolism vol. 15,1 (2017): e40614. doi: https://doi.org/10.5812/ijem.40614
Ansari S, Djalali M, Mohammadzadeh Honarvar N, Mazaherioun M, Zarei M, Agh F, Gholampour Z, Javanbakht MH. The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Int J Endocrinol Metab. 2017 Jan 21;15(1):e40614. doi: 10.5812/ijem.40614. eCollection 2017 Jan. PMID: 28835761; PMCID: PMC5554612.
Copy Download .nbib Format: NLM
Share it on

Int J Endocrinol Metab. 2017 Jan 21;15(1):e40614. doi: 10.5812/ijem.40614. eCollection 2017 Jan.

The Effect of n-3 Polyunsaturated Fatty Acids Supplementation on Serum Irisin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.

International journal of endocrinology and metabolism

Samaneh Ansari, Mahmoud Djalali, Niyaz Mohammadzadeh Honarvar, Maryam Mazaherioun, Mahnaz Zarei, Fahimeh Agh, Zahra Gholampour, Mohammad Hassan Javanbakht

Affiliations

  1. Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, IR Iran.
  2. Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, International Campus, Tehran University of Medical Sciences, Tehran, IR Iran.
  3. Faculty of Nutritional Sciences and Dietetics, Iran University of Medical Sciences, Tehran, IR Iran.
  4. Farahzad Health Care Center, Iran University of Medical Sciences, Tehran, IR Iran.

PMID: 28835761 PMCID: PMC5554612 DOI: 10.5812/ijem.40614

Abstract

BACKGROUND: Diabetes refers to a group of metabolic diseases with blood glucose of higher than normal ranges. Furthermore, n-3 polyunsaturated fatty acids are necessary for the regulation of the activity of human function. The effect of n-3 PUFA on diabetes has been investigated in animal studies, yet, the exact amount has not been set, to date. Irisin, as a new myokine, is released from skeletal muscle and Irisin levels decrease as a result of physical inactivity, overweightness, and obesity. Also, the reduction of serum irisin level is associated with development of insulin resistance and type 2 diabetes. This study was performed to assess the effects of n-3 PUFA supplementation on serum irisin level in patients with diabetes.

METHODS: This randomized clinical trial included 43 patients with type 2 diabetes (21 patients in the placebo group and 22 patients in the n-3 PUFA supplement group). They were randomized to groups, one receiving 10 weeks of either n-3 PUFA supplement and the other the placebo (1250 mg capsule, three times per day). Samples were also matched by age, gender, and body mass index (BMI) in the 2 groups. Anthropometric measurements, demographic information and dietary intakes were obtained both before and after the intervention. Serum irisin levels were measured before and after the intervention using human irisin enzyme linked immunosorbent assay (ELISA) kit. Independent t-test was used to compare the mean outcomes between groups.

RESULTS: At baseline, irisin serum levels were not significantly different between the placebo and n-3 PUFA supplementation groups (P > 0.05). However, a significant change was observed between the groups after intervention (P = 0.04). Also there was a significant difference in mean change (after versus before the intervention) (P = 0.05). Compared to the placebo, n-3 PUFA supplementation decreased serum FBS and HbA1C (P = 0.036 and 0.001; respectively). Also, there were significant differences between changes of diastolic blood pressure and HOMA-IR after the intervention between the groups. The duration of illness was not considered as a confounding factor because there was no significant association between irisin level (after versus before the intervention) and the illness duration.

CONCLUSIONS: The current study indicated that n-3 PUFA supplementation with a dosage of 1250 mg three times per day, resulted in increased serum irisin level of diabetic patients.

Keywords: Docosahexaenoic Acid (DHA); Eicosapentaenoic Acid (EPA); Irisin; Myokine; Type 2 Diabetes; n-3 Poly Unsaturated Fatty Acids

Conflict of interest statement

Conflict of Interest:The authors declare that they had no conflict of interest.

References

  1. Int J Endocrinol. 2013;2013:746281 - PubMed
  2. J Diabetes Complications. 2013 Jul-Aug;27(4):365-9 - PubMed
  3. Eur Rev Med Pharmacol Sci. 2015;19(2):316-21 - PubMed
  4. Nutr Res Pract. 2014 Apr;8(2):177-82 - PubMed
  5. Ann Nutr Metab. 2013;63(1-2):60-1 - PubMed
  6. Lipids Health Dis. 2015 Jan 10;14:1 - PubMed
  7. Curr Obes Rep. 2014 Feb 02;3:235-41 - PubMed
  8. Tohoku J Exp Med. 2014;233(2):135-40 - PubMed
  9. Metabolism. 2013 Aug;62(8):1037-44 - PubMed
  10. Peptides. 2013 Jan;39:125-30 - PubMed
  11. PLoS One. 2014 Apr 07;9(4):e94235 - PubMed
  12. Nature. 2012 Jan 11;481(7382):463-8 - PubMed
  13. Z Ernahrungswiss. 1998;37 Suppl 1:1-7 - PubMed
  14. J Clin Endocrinol Metab. 2013 Apr;98(4):E769-78 - PubMed
  15. PLoS One. 2014 Apr 11;9(4):e94463 - PubMed
  16. PLoS One. 2013 Sep 02;8(9):e72858 - PubMed
  17. J Diabetes Res. 2015;2015:359159 - PubMed
  18. Obes Res. 2003 Oct;11(10 ):1182-91 - PubMed
  19. J Huazhong Univ Sci Technolog Med Sci. 2009 Apr;29(2):139-43 - PubMed
  20. Diabetes Res Clin Pract. 2013 Apr;100(1):96-101 - PubMed
  21. J Appl Physiol (1985). 2007 Sep;103(3):1093-8 - PubMed

Publication Types